THY1 (Thy-1 membrane glycoprotein)

NCAM-positive NCLCs derived from hiPSCs enhance peripheral nerve regeneration through vascularization and Schwann cell-mediated remyelination, resulting in structural and functional recovery equivalent to autografts. This strategy offers a safe, scalable alternative to donor nerve harvest, and integration with bioengineered conduits could further expand clinical applicability in peripheral nerve reconstruction.

The gap between pre‑clinical findings and clinical applications highlights the need for further investigation. Extensive research is still required to elucidate how therapeutic interventions achieve efficacy, ensure safety, and identify optimal strategies for targeting different organs in combination with other pharmacological agents.

Upon a 48-hour treatment with carboplatin and/or paclitaxel, HGSC cells in tri-component tumoroids exhibited higher chemoresistance than HGSC-only tumoroids. Generated using a 384-well hanging drop array, these tri-component tumoroids are compatible with high-throughput drug screening. This versatile platform can be adapted for a range of stromal cell types, making it broadly applicable for studying ovarian as well as other solid tumor microenvironments.

We concluded for the first time that the combination of SOR and ASH-AE generates antagonistic antitumor effect in HepG2 cells. Moreover, ASH-AE can inhibit proliferation of HepG2 cells and mitigate sorafenib-induced resistance-associated markers in HepG2 cells by targeting CD90+ cells via Hedgehog pathway modulation.

Effect of Baicalein on Odontogenic Differentiation of Dental Pulp Stem Cells: An In Vitro Study. Int J Clin Pediatr Dent 2026;19(1):92-99.

This study comprehensively characterized the molecular features of BCSCs through multi-omics approaches, identified reliable surface markers and key regulatory genes, and constructed a prognostic prediction model with clinical application value.

Finally, molecular docking studies indicated that dihydroergotamine might be a promising candidate drug for targeting DAB2. This study systematically investigated the expression changes of angiogenesis genes in HCC, constructed a tumor prognosis prediction model, and explored potential therapeutic targets and drugs. These findings are of significance for guiding the selection of treatment options and identifying therapeutic targets for HCC.

THY1⁺ CAFs represent a proangiogenic subset that drives PCa progression via the CXCL6/CXCR2 axis and THY1-mediated VEGFA expression. These findings highlight stromal THY1 and the CXCL6/CXCR2 pathway as potential therapeutic targets.

To determine the role of neuronal TrkB in adult oligodendrogenesis in the older brain, we generated Thy1-CreERT2-EYFP::TrkBfl/fl mice and administered tamoxifen at 12-months of age, before cumulative EdU labelling...However, there was a significant decrease in the proportion of proliferative OPCs that contributed to the post-mitotic oligodendrocyte population in the somatosensory cortex 5-months later. These findings provide insight into regional and age-related changes in oligodendroglial population dynamics and identify that neuronal TrkB supports cortical oligodendrogenesis during healthy brain aging.

Furthermore, CTCs provide a platform for companion diagnostics by reflecting mutational and resistance profiles, particularly in the context of targeted therapies and immune checkpoint inhibitors. Despite current limitations in standardization, sensitivity, and scalability, the integration of CTC analysis into clinical practice holds potential to enhance precision medicine strategies in HCC.

This work discovered the precise epigenetic mechanism involving histone methylation responsible for such changes in MSC phenotype. By inhibiting the histone methylation by GSK343, this study showed that MSC phenotype can be maintained over serial passaging as demonstrated by microscopy, multi-omics, and in vitro functional assays.

This study opens promising avenues for developing targeted therapeutic strategies aimed at inhibiting the invasive and osteoclastogenic functions of CD90+PDPN+ FLSs in PVNS. Future research should focus on validating these cells as potential therapeutic targets, possibly through the use of selective inhibitors, which could help mitigate synovial hyperplasia and bone destruction in affected patients.